Contineum Therapeutics (NASDAQ: CTNM) net income
Contineum Therapeutics reported a net loss of $60.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $42.3m. Earnings per share were −$2.17.
Contineum Therapeutics's best year of the last 3 was fiscal 2023. It reported a loss in 2 of those 3 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$60.0m | — | — | −$2.17 |
| 2024 | −$42.3m | −286.0% | — | −$2.18 |
| 2023 | $22.7m | — | 45.4% | $1.36 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Contineum Therapeutics net income compared with its sector
By net income for its latest fiscal year, Contineum Therapeutics ranks 276th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 274th | Onkure Therapeutics | −$59.5m | −1,729.6% |
| 275th | Climb Bio | −$59.9m | — |
| 276th | Contineum Therapeutics | −$60.0m | — |
| 277th | Fulgent Genetics | −$60.5m | −18.8% |
| 278th | STLN | −$60.6m | −12.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Contineum Therapeutics
- How much did Contineum Therapeutics earn in fiscal 2025?
- Contineum Therapeutics reported a net loss of $60.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $42.3m.
- What are the earnings per share of Contineum Therapeutics?
- They were −$2.17 in fiscal 2025, compared with −$2.18 in fiscal 2024.
- What was the most profitable year for Contineum Therapeutics?
- Of its last 3 fiscal years, fiscal 2023, with $22.7m.
- Where does Contineum Therapeutics rank in its sector by net income?
- It ranks 276th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Contineum Therapeutics come from?
- From the annual report (Form 10-K) that Contineum Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Contineum Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Contineum Therapeutics: the Contineum Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.